新冠肺炎疫苗融资机制、新冠肺炎预先市场承诺（AMC）和新冠肺炎病毒支柱交付工作的评估：最终报告

Final Report April2025 Prepared forGavi, WHO, UNICEF, CEPIPrepared byRTI International3040 E. Cornwallis Road, PO Box 12194Research Triangle Park, NC 27709 USAwww.rti.orgWith Itad Ltd. (UK) and Genesis Analytics (S. Africa) ManagementandImplementationof the Evaluation The Gavi Secretariat on behalf of andwithparticipationofThe Coalition for EpidemicPreparedness Innovations (CEPI), Gavi, the Vaccine Alliance(Gavi), the World HealthOrganization (WHO), and the United Nations Children’s Fund (UNICEF)commissioned theevaluation. RTI International (RTI)was contracted to conduct the evaluation, with support fromItad and Genesis. IndependentEvaluation Team •Rebecca Flueckiger, Team Lead (RTI)•Mathew Cooper, Team Deputy Team Lead (Itad)•Martin Osumba, Country Engagement Lead (RTI)•Susannah Clarke-von Witt, Country Case StudyResearch Lead (Genesis)•Helen Merati, Learning Lead (Itad) •Lamiaa Shehata, Programme Manager and PartB Evaluation Co-Lead (Itad)•Meghan Bishop, Part B Evaluation Co-Lead(Itad)•Joanna Springer,Systems EvaluationAdvisor(RTI) Delivery Evaluation Partnership Group •Laura Craw (Gavi)•Ann Lindstrand (WHO)•Richard Mihigo (Gavi)•Beth-Ann Plowman (UNICEF)•Riccardo Polastro (WHO) •Roxana Prisacaru (CEPI)•Benjamin Schreiber (UNICEF)•Marta Urrutxi Gallastegi (Gavi)•Alba Vilajeliu (WHO) Acknowledgments Theevaluation teamwould like to expressoursincere gratitude toGaviCentralized EvaluationTeam,UNICEF, WHO,CEPI, and country focal pointsfor their invaluable guidance throughoutthe evaluation process. We are particularly thankful to theDelivery EvaluationPartnershipGroup, the Evaluation Steering Committee, and the Evaluation Advisory Committee for theirconstructive feedback and thoughtful contributions.Special thanks are extended to LeslieMoreland,Aude Mommeja, andAndersAmaechi, whose exceptional generosity in sharing theirexpertise, experience, and time has been instrumental to the success of this evaluation. Theevaluation teamisalsograteful to Sinan Hatik, Christina Meyers, AnikaHannan,MarcTully, Arun Kumar,David Walker,Shriya Samani, Erin Power, Nadege AtkinsandGuhadMuhammad Adan,for their work supporting data collection and analysis.Additional thanks toAlan O’Conner, Sam McPherson andDrSaul Johnson for quality assurance.Wewould also liketo thankReconstra,SalimaBacchus-Hinds, ISIDA,DrBoris Gbehi, Madonna Emmanuel,DrJessica Oyugi, andDrRediet Gebrehiwotfor their work on the country case studies. Above all,the evaluation teamwishesto express deep appreciation to the key informants whogenerously participated in interviews. This includes members of the Gavi Board, AlliancePartners, donors, experts, country partners, and representatives of private sector partnerships.The team istruly grateful for the valuable information, insights, and wisdom they shared. Disclaimer The views expressed in this report are those of the evaluators. They do not represent those ofGavi, UNICEF, WHO, CEPI,or any of the individuals and organizations referred to in this report. EXECUTIVE SUMMARYI PART 1: INTRODUCTION, EVALUATION DESIGN AND METHODOLOGY 1Introduction.............................................................................................................................................................1 Background..............................................................................................................................................1Purpose Objective and Scope of the Evaluation.......................................................................................5Structure of this Report...........................................................................................................................10 Country Case Study Approach...............................................................................................................18Learning Priorities...................................................................................................................................19Validation and Sense-making.................................................................................................................19Triangulation of Insights and Recommendation Development................................................................20Ethics......................................................................................................................................................20Risks and Limitations..............................................................................................................................21 PART 2: EVALUATION FINDINGS22Implementation and Adaptation............................................................................................................................23 EQ 1: How successfully was the COVAX Facility and AMC implemented, relative tooverarching objectives and the changing implementation context?........................................................23EQ 2: How effectively were COVAX Facility and A